These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 24180275)
21. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed. Zanjirband M; Rahgozar S Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669 [TBL] [Abstract][Full Text] [Related]
22. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Shangary S; Wang S Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305 [TBL] [Abstract][Full Text] [Related]
23. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593 [TBL] [Abstract][Full Text] [Related]
24. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575 [TBL] [Abstract][Full Text] [Related]
25. An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy. Li H; Cai X; Yang X; Zhang X Eur J Med Chem; 2024 Jun; 272():116506. PubMed ID: 38761584 [TBL] [Abstract][Full Text] [Related]
26. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. Sirous H; Chemi G; Campiani G; Brogi S Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433 [TBL] [Abstract][Full Text] [Related]
27. MDM2 inhibitors for pancreatic cancer therapy. Azmi AS; Philip PA; Almhanna K; Beck FW; Sarkar FH; Mohammad RM Mini Rev Med Chem; 2010 Jun; 10(6):518-26. PubMed ID: 20377522 [TBL] [Abstract][Full Text] [Related]
28. Small-molecule inhibitors of MDM2 as new anticancer therapeutics. Dickens MP; Fitzgerald R; Fischer PM Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042 [TBL] [Abstract][Full Text] [Related]
29. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies. Bandaru S; Ponnala D; Lakkaraju C; Bhukya CK; Shaheen U; Nayarisseri A Asian Pac J Cancer Prev; 2015; 16(9):3759-65. PubMed ID: 25987034 [TBL] [Abstract][Full Text] [Related]
30. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Gupta A; Shah K; Oza MJ; Behl T Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517 [TBL] [Abstract][Full Text] [Related]
31. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? Haronikova L; Bonczek O; Zatloukalova P; Kokas-Zavadil F; Kucerikova M; Coates PJ; Fahraeus R; Vojtesek B Cell Mol Biol Lett; 2021 Dec; 26(1):53. PubMed ID: 34911439 [TBL] [Abstract][Full Text] [Related]
32. Inhibitors of MDM2 and MDMX: a structural perspective. Riedinger C; McDonnell JM Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995 [TBL] [Abstract][Full Text] [Related]
33. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy. Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735 [TBL] [Abstract][Full Text] [Related]
34. Recent advances in validating MDM2 as a cancer target. Rayburn ER; Ezell SJ; Zhang R Anticancer Agents Med Chem; 2009 Oct; 9(8):882-903. PubMed ID: 19538162 [TBL] [Abstract][Full Text] [Related]
36. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148 [TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Li Q; Lozano G Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034 [TBL] [Abstract][Full Text] [Related]
38. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach. Di J; Zhang Y; Zheng J Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075 [TBL] [Abstract][Full Text] [Related]
39. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction. Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989 [TBL] [Abstract][Full Text] [Related]